Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $11.00.

Separately, Weiss Ratings raised shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th.

Evaxion A/S Price Performance

NASDAQ:EVAX opened at $3.34 on Tuesday. The business’s 50-day moving average price is $3.10 and its 200 day moving average price is $3.54. The firm has a market cap of $27.86 million, a P/E ratio of -2.76 and a beta of 0.26. Evaxion A/S has a 52-week low of $2.77 and a 52-week high of $12.15. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in EVAX. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Evaxion A/S in the first quarter valued at $112,000. Renaissance Technologies LLC bought a new stake in shares of Evaxion A/S during the 1st quarter worth $146,000. Finally, Rathbones Group PLC bought a new stake in shares of Evaxion A/S during the 1st quarter worth $170,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a Denmark-based biotechnology company that develops immunotherapies and vaccines using artificial intelligence. Its proprietary AI-Immunology platform is designed to analyze biological data, identify disease targets and support the development of treatments tailored to individual patients or specific pathogens.

The company’s research has focused primarily on personalized cancer vaccines and vaccines for infectious diseases. Its pipeline has included EVX-01, an individualized cancer immunotherapy candidate intended to stimulate a patient’s immune system to recognize and attack tumor-specific targets, as well as additional programs directed at cancer and infectious diseases.

Evaxion was founded in Denmark and conducts its research and development activities from the country, serving the international biotechnology and pharmaceutical markets.